-
-
-
-
-
-
-
Cantor Fitzgerald Reiterates Overweight Rating on Tyra Biosciences (TYRA)
-
-
-
-
-
-
-
Oppenheimer Assumes Tyra Biosciences (TYRA) at Outperform
-
-
-
-
-
-
-
Piper Sandler on Tyra Biosciences (TYRA): 'We're incrementally positive on dabogratinib's commercial opportunity'
-
-
-
-
-
-
-
Piper Sandler Highlights Top Picks in the Biopharma 2026 Preview Note
-
-
-
-
-
-
-
Piper Sandler Assumes Tyra Biosciences (TYRA) at Overweight
-
-
-
-
-
-
-
Biopharma 2025 Preview: 'Piper Sandler Sees Lots of Upside Opportunity'
-
-
-
-
-
-
-
BofA Securities Upgrades Tyra Biosciences (TYRA) to Buy
-
479,031 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All


